Last updated 5 days ago

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

200 patients around the world

Available in Puerto Rico, Argentina, United States

Eli Lilly and Company

8Research sites

200Patients around the world

This study is for people with

Obesity

Diabetes

Diabetes mellitus type 2

To 75 Years

All Gender

: Have type 2 diabetes.
Have an HbA1c ≥7.5% to ≤10.5% at screening.
Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening.
Diet and exercise.
Stable dose of metformin.
Sodium-glucose cotransporter-2 (SGLT2) inhibitor.
Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening.
Have a BMI of 27 or greater at screening.

: Have any form of diabetes other than type 2 diabetes.
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
Have any of the following cardiovascular conditions within 3 months prior to screening.
Acute myocardial infarction.
Cerebrovascular accident (stroke).
Unstable angina.
Hospitalization due to congestive heart failure.
Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include.
Basal or squamous cell skin cancer.
In situ carcinomas of the cervix.
In situ prostate cancer.
Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months.
Amylin RA.
Dual amylin and calcitonin RA.
Glucagon-like peptide-1 receptor (GLP-1) RA.
Glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA.
GLP-1/glucagon (GCG) RAs.
GIP/GLP-1/GCG RAs.
Have used excluded antihyperglycemic medications within 3 months prior to screening.
Have used insulin for diabetic control within the prior year.

Instituto de Investigaciones Clínicas Córdoba

Dean Funes 1161, Córdoba

Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires

Viamonte 2278, C1056ABJ Cdad. Autónoma de Buenos Aires, Argentina

CEDIC Centro de Investigación Clínica - CABA, Buenos Aires

Jerónimo Salguero 2142, CABA, Buenos Aires

Go Centro Médico San Nicolás

San Nicolás, Buenos Aires, Argentina, 2900

Centro Medico de Nutrición y Diabetes (CENUDIAB)

Av. J. B. Alberdi 5763, CABA, Buenos Aires

Clínica Universitaria Privada Reina Fabiola - Córdoba

Oncativo 1248, X5004FHP Córdoba, Argentina

Escuela de Medicina San Juan Bautista

6W9X+WH2, Autop. Luis A. Ferré, Caguas, 00727

MGCENDO LLC

Calle Ebano I-4 Caparra Hills GUAYNABO, Puerto Rico 00968

SponsorEli Lilly and Company

Study typeInterventional

Conditions

ObesityDiabetes mellitus type 2

Requirements

To 75 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07215559